Neuroone Medical Technologies Corp NMTC
We take great care to ensure that the data presented and summarized in this overview for NEUROONE MEDICAL TECHNOLOGIES Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NMTC
View all-
Vanguard Group Inc Valley Forge, PA920KShares$1.06 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$358,4070.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il81.8KShares$94,0720.0% of portfolio
-
State Street Corp Boston, MA59.5KShares$68,4230.0% of portfolio
-
Blair William & CO Chicago, IL55.6KShares$63,8890.0% of portfolio
-
Mai Capital Management50KShares$57,4990.0% of portfolio
-
Jane Street Group, LLC New York, NY40KShares$45,9430.0% of portfolio
-
Northern Trust Corp Chicago, IL30.3KShares$34,8230.0% of portfolio
-
Xtx Topco LTD London, X018.5KShares$21,2980.0% of portfolio
-
Princeton Global Asset Management LLC16.8KShares$19,3570.0% of portfolio
Latest Institutional Activity in NMTC
Top Purchases
Top Sells
About NMTC
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Insider Transactions at NMTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,376
-4.3%
|
$7,376
$1.16 P/Share
|
|
Feb 18
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,812
-0.62%
|
$1,812
$1.16 P/Share
|
|
Feb 18
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
71,325
-6.28%
|
$71,325
$1.16 P/Share
|
|
Feb 14
2025
|
Paul Buckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,778
+16.88%
|
-
|
|
Feb 14
2025
|
Edward Andrle Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,778
+23.19%
|
-
|
|
Feb 14
2025
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,778
+19.54%
|
-
|
|
Jan 31
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
252
-0.15%
|
$252
$1.15 P/Share
|
|
Jan 31
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.03%
|
$90
$1.15 P/Share
|
|
Jan 31
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,239
-0.2%
|
$2,239
$1.15 P/Share
|
|
Dec 31
2024
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.12%
|
$0
$0.83 P/Share
|
|
Dec 31
2024
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-0.67%
|
$0
$0.83 P/Share
|
|
Dec 31
2024
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
4,697
-0.41%
|
$0
$0.83 P/Share
|
|
Nov 30
2024
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
252
-0.15%
|
$0
$0.62 P/Share
|
|
Nov 30
2024
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.03%
|
$0
$0.62 P/Share
|
|
Nov 30
2024
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,239
-0.2%
|
$0
$0.62 P/Share
|
|
Oct 31
2024
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
252
-0.15%
|
$0
$0.97 P/Share
|
|
Oct 31
2024
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.03%
|
$0
$0.97 P/Share
|
|
Oct 31
2024
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,239
-0.2%
|
$0
$0.97 P/Share
|
|
Sep 30
2024
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-0.66%
|
$0
$0.99 P/Share
|
|
Sep 30
2024
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.12%
|
$0
$0.99 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 111K shares |
|---|
| Payment of exercise price or tax liability | 151K shares |
|---|---|
| Open market or private sale | 28K shares |